<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330472</url>
  </required_header>
  <id_info>
    <org_study_id>A6131025</org_study_id>
    <nct_id>NCT01330472</nct_id>
  </id_info>
  <brief_title>An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites</brief_title>
  <official_title>An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study Of Xanax XR Tablet 3 mg (Sourced From Caguas) Versus Xanax XR Tablet 3 mg (Sourced From Barceloneta) In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate if Xanax sustained release tablets manufactured at two different sites
      provide similar drug levels in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from time zero to infinity (AUCinf) of alprazolam</measure>
    <time_frame>Predose, and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma conc (Cmax) of alprazolam</measure>
    <time_frame>Predose, and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from zero to the last time point (AUClast) of alprazolam</measure>
    <time_frame>Predose, and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve extrapolated (AUC%extrap) of alprazolam</measure>
    <time_frame>Predose, and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life of alprazolam</measure>
    <time_frame>Predose, and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak concentration (Tmax) of alprazolam</measure>
    <time_frame>Predose, and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Xanax XR tablets 3 mg (sourced from Caugus)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xanax XR tablets 3 mg (sourced from Barceloneta),</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xanax XR tablets 3 mg (sourced from Caugus)</intervention_name>
    <description>Tablets, 3 mg, single dose</description>
    <arm_group_label>Xanax XR tablets 3 mg (sourced from Caugus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xanax XR tablets 3 mg (sourced from Barceloneta)</intervention_name>
    <description>Tablets, 3 mg, single dose</description>
    <arm_group_label>Xanax XR tablets 3 mg (sourced from Barceloneta),</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 20 and 55 years, inclusive.

          -  An informed consent document signed and dated by the subject.

        Exclusion Criteria:

          -  Evidence or history of clinically significant abnormality.

          -  A positive urine drug screen.

          -  Subjects who are hypersensitive to alprazolam or related compounds.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6131025&amp;StudyName=An%20Bioequivalence%20Study%20Of%20Xanax%20Extended%20Release%20Tablets%20From%20Two%20Different%20Manufacturing%20Sites</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alprazolam</keyword>
  <keyword>Xanax</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Panic disorder with or without agoraphobia.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

